← Back to Search

Survivors of early-onset colorectal cancer, with recurrent disease (Training Cohort) for Colorectal Cancer (ENCORE Trial)

N/A

Waitlist Available

Led By Ajay Goel, PhD

Research Sponsored by City of Hope Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 120 months

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to help young adults who survived early-onset colorectal cancer by using a test that looks at tiny molecules in their tumors. The test uses computer algorithms to predict if and when the cancer might come back, helping doctors make better decisions about monitoring and treatment.

Eligible Conditions

Colorectal Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 120 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 120 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 120 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Recurrence Free Survival

Secondary study objectives

Overall Survival

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups

Experimental Treatment

Group I: Survivors of early-onset colorectal cancer, with recurrent disease (Validation Cohort)Experimental Treatment1 Intervention

Survivors of early-onset colorectal cancer who developed recurrent CRC within 60 months from primary tumor treatment, in the second, independent, validation cohort

Group II: Survivors of early-onset colorectal cancer, with recurrent disease (Training Cohort)Experimental Treatment1 Intervention

Survivors of early-onset colorectal cancer who developed recurrent CRC within 60 months from primary tumor treatment, in the first cohort

Group III: Survivors of early-onset colorectal cancer, with no recurrent disease (Validation Cohort)Experimental Treatment1 Intervention

Survivors of early-onset colorectal cancer who did not develop recurrent CRC within 60 months from primary tumor treatment, in the second, independent, validation cohort

Group IV: Survivors of early-onset colorectal cancer, with no recurrent disease (Training Cohort)Experimental Treatment1 Intervention

Survivors of early-onset colorectal cancer who did not develop recurrent CRC within 60 months from primary tumor treatment, in the first cohort

Do I qualify?Apply below to find out